JPS58131913A - Preparation of lyophilized erythrocyte - Google Patents

Preparation of lyophilized erythrocyte

Info

Publication number
JPS58131913A
JPS58131913A JP57013862A JP1386282A JPS58131913A JP S58131913 A JPS58131913 A JP S58131913A JP 57013862 A JP57013862 A JP 57013862A JP 1386282 A JP1386282 A JP 1386282A JP S58131913 A JPS58131913 A JP S58131913A
Authority
JP
Japan
Prior art keywords
red blood
blood cells
erythrocyte
freeze
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57013862A
Other languages
Japanese (ja)
Other versions
JPH0459299B2 (en
Inventor
Yatsuhiro Kamimura
上村 八尋
Kazumi Fukuyama
福山 和美
Katsuhiro Uryu
瓜生 勝寛
Tomiyuki Matsunaga
松永 富行
Tsunetaka Nakajima
中島 常隆
Takuji Doi
土居 卓治
Masakazu Tajima
田島 政和
Satoru Funakoshi
船越 哲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Priority to JP57013862A priority Critical patent/JPS58131913A/en
Publication of JPS58131913A publication Critical patent/JPS58131913A/en
Publication of JPH0459299B2 publication Critical patent/JPH0459299B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PURPOSE:To obtain lyophilized erythrocyte having stbility for a long-term storage with preventing the denaturation of erythrocyte during drying, by adding a specific amount of albumin to a water dispersion of erythrocyte, followed by lyophilization. CONSTITUTION:Albumin is added to a water dispersion of erythroctye (preferably sensitized erythrocyte or fixed erythrocyte) in such a way that the concentration of albumin is >=2%(w/v), preferably 3-6%, and the erythrocyte is lyophilized. A dispersion of distilled water, a dispersion of physiologic salt solution, an isotonic buffer solution of phosphoric acid may be cited as the water dispersion. In case of sensitized erythrocyte used as a reagent, etc. for detecting an antigen or an antibody, it shows no reduction in detection sensitivity during lyophilization, is stable for a long-term storage, and usable as various kinds of reagents for hemaggulutination.

Description

【発明の詳細な説明】 本発#3は、安定なる赤血球凍結乾燥物を効率よく製造
する方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention #3 relates to a method for efficiently producing a stable lyophilized red blood cell.

赤血球の水中浮遊液を凍結乾燥してこれを凍結乾燥物と
しfc場合、赤血球が変性する0この変性が問題となる
のは、特に赤血球に抗原又は抗体を感作させた感作赤血
球、赤血球tフォルムアルデヒド、グルタルアルデヒド
などで処理した固定化赤血球である。
When a suspension of red blood cells in water is freeze-dried and this is used as a freeze-dried product, the red blood cells are denatured.This denaturation is particularly problematic for sensitized red blood cells and red blood cells that have been sensitized with antigens or antibodies. Fixed red blood cells treated with formaldehyde, glutaraldehyde, etc.

ところで感作赤血球等は、抗原又は抗体を検出するため
の試薬(例えは、受身赤血球凝集反応試薬、逆受身赤血
球凝集反応試薬、赤血球凝集阻止反応試薬等)などとし
て利用されている。〔ピアス、G、N、及びシュルマン
I N、  R,(Vyaa。
By the way, sensitized red blood cells and the like are used as reagents (for example, passive hemagglutination reagents, reverse passive hemagglutination reagents, hemagglutination inhibition reagents, etc.) for detecting antigens or antibodies. [Pierce, G.N., and Shulman I.N.R. (Vyaa.

G、 N−and Shulmin、 N= R,) 
 :サイエンス(Science)、  170.33
2.1970 及び合弁光信、高橋隆、外「受身赤血球
凝集反応によるAu抗体の検出」、医学のあゆみ78,
759.1971)。
G, N-and Shulmin, N= R,)
:Science, 170.33
2.1970 and Mitsunobu Joint Venture, Takashi Takahashi, et al. “Detection of Au antibodies by passive hemagglutination reaction”, History of Medicine 78,
759.1971).

しかしこれらの検出試薬に使用される赤血球、特に感作
赤血球は不安定である。特に水浮遊液の状態では短期間
で使用に耐えない程度にまで抗原又は抗体検出感度が低
下する。これを防止するためには感作赤血球の水浮遊液
を凍結乾燥することが望ましい。細醒やその他の細胞の
凍結乾燥の安定化に際して0.5〜1%のアルブミンや
アミノ酸、糖類ktljs加後凍結戦後凍結乾燥化を図
っている0(太田勇夫ら、真空技術講座8、真空乾燥、
日刊工業新聞社、昭和39年)o  Lかしこの条件を
たとえは感作赤血球水浮遊液に応用した場合、凍結乾燥
後の感作赤血球の検出′感度は表1に示す如く1/8〜
l/16低下する。
However, the red blood cells used in these detection reagents, especially sensitized red blood cells, are unstable. Particularly in the state of aqueous suspension, the antigen or antibody detection sensitivity decreases in a short period of time to the extent that it cannot be used. In order to prevent this, it is desirable to freeze-dry the aqueous suspension of sensitized red blood cells. When stabilizing the freeze-drying of cells such as sub-awakening and other cells, 0.5 to 1% of albumin, amino acids, and sugars KTLJs are added and freeze-dried after freezing.0 (Isao Ota et al., Vacuum Technology Course 8, Vacuum Drying ,
Nikkan Kogyo Shimbun, 1962) If these conditions are applied to a sensitized red blood cell aqueous suspension, the detection sensitivity of sensitized red blood cells after freeze-drying will be 1/8 to 1/8 as shown in Table 1.
It decreases by l/16.

また、固定赤血球は、例えは前述の感作赤血球のIel
lなどに使用されるか、これの水浮遊液管凍結乾燥すれ
ば実施例15にも示したように固定赤血球が変性1来た
す。
In addition, fixed red blood cells may be used, for example, as the above-mentioned sensitized red blood cells.
The fixed red blood cells are denatured (1) as shown in Example 15 if the red blood cells are used in water suspension tubes or freeze-dried.

そこで、本発明者らは赤血球、特に感作赤血球、固定赤
血球の凍結乾燥時の安定化全図るべく研究を重ねた。そ
の結果、赤血球水浮遊液(就中、感作赤血球水浮遊液、
固定赤血球水浮遊液)にアルブミン’に2%(w/v)
濃度以上となるように加えて凍結乾燥することにより、
凍結乾燥時に赤血球が変性することがなく、特に感作赤
血球にあっては凍結乾燥時に当該感作赤血球による検出
感度の低下を来たすことがなく、シかもかくして得られ
た凍結乾燥物は長期保存によっても、変性1来たさず、
安定なものであること?見出した。
Therefore, the present inventors have conducted extensive research to fully stabilize red blood cells, particularly sensitized red blood cells, and fixed red blood cells during freeze-drying. As a result, red blood cell water suspension (in particular, sensitized red blood cell water suspension,
2% (w/v) of albumin' in fixed red blood cell aqueous suspension)
By adding it to a concentration higher than that and freeze-drying it,
Red blood cells do not denature during freeze-drying, and detection sensitivity of sensitized red blood cells does not decrease during freeze-drying. Also, degeneration 1 did not come,
Does it have to be stable? I found it.

本発明はかかる知見に基づいて完成さ扛たものであり、
赤血球の水浮遊液にアルブミンt−2%(w/v)濃度
以上となるように添加して凍結乾燥することによる赤血
球凍結乾燥物の製造法に関するO 本発明にて使用される赤血球は、その動物種の由来に制
限はなく、例えは哺乳類(例えは、ヒト、ウシ、ウサギ
、マウス、′ウマ、ヒツジ)、鳥類2(例えは、ニワト
リ入祉虫類などの由来のものが使用される。また、当該
赤血球は抗原(例えは、HBa抗JQ 、HB eFC
涼、サイログロブリン)、抗体(例えば、抗インターフ
ェロン抗体、抗ウロキナーゼ抗体、抗アルファ7エトプ
ーテン)t−感作した感作赤血球、フォルムアルデヒド
、グルタルアルデヒドなどで処理した固定赤血球゛など
の修飾された赤血球であってもよい。
The present invention has been completed based on such knowledge,
The red blood cells used in the present invention are as follows: There is no restriction on the origin of the animal species, and for example, those derived from mammals (for example, humans, cows, rabbits, mice, horses, and sheep), birds2 (for example, chickens, etc.) are used. In addition, the red blood cells are infected with antigens (for example, HBa anti-JQ, HB eFC
with modified red blood cells such as t-sensitized sensitized red blood cells, fixed red blood cells treated with formaldehyde, glutaraldehyde, etc. There may be.

赤血球の水浮遊液としては、蒸留水浮遊液、生理食塩液
浮遊液、等張化リン酸緩衝液などがあげられる。当該浮
遊液は自体既知の操作にて調製さされる。
Examples of red blood cell suspensions in water include distilled water suspensions, physiological saline suspensions, and isotonic phosphate buffer solutions. The suspension is prepared by a procedure known per se.

本発明で使用されるアルブミンは、その動物種の由来に
特に制限はなく、−数的に扛赤血球について例示した如
き動物種由来のものが使用される。
The origin of the albumin used in the present invention is not particularly limited as to the animal species, and those derived from the animal species numerically exemplified for erythrocytes can be used.

アルブミンの添加量は、当該浮遊液中におけるアルブミ
ンが2%(W/v)濃度以上、好ましくは3qb(W/
V)濃度以上となるに相当する量である。アルブミンが
3%(W/V)llk度以上の場合には凍結乾燥時の変
性防止のみならず、保存安定性も著しく増大する。アル
ブミン添加量の上限については特に制限はないが、鮭済
的見地からは8チ(w/v)濃度、好ましくは6%(w
/v)濃度である。
The amount of albumin added is such that the concentration of albumin in the suspension is 2% (W/v) or more, preferably 3qb (W/v).
V) The amount corresponding to the concentration or higher. When the albumin content is 3% (W/V) or more, it not only prevents denaturation during freeze-drying but also significantly increases storage stability. There is no particular restriction on the upper limit of the amount of albumin added, but from a salmon management perspective, it should be 8% (w/v) concentration, preferably 6% (w/v).
/v) concentration.

当該アルブミン添加赤血球水浮遊液の凍結乾燥鉱自体既
知の操作にて行えはよい。
Freeze-drying of the albumin-added red blood cell water suspension can be carried out using known procedures.

かくして得られた凍結乾燥物は、凍結乾燥によって赤血
球の変性を来たすことがなく、シかも長期保存に対して
も安定である。特に感作赤血球にあっては、凍結乾燥時
に検出感度の低下がみられず、長期保存に対しても安定
なものであるから、各種の赤血球凝集反応試薬に利用す
ることができるものである。
The lyophilized product thus obtained does not cause denaturation of red blood cells by lyophilization and is stable even during long-term storage. In particular, sensitized red blood cells do not show a decrease in detection sensitivity during freeze-drying and are stable even during long-term storage, so they can be used in various reagents for red blood cell agglutination reactions.

実施例1 HBa抗*+W性血漿より、硫安分画法、イオン交換ク
ロマトグラフィー法および超遠心分離法%全組合せた方
法により布製HBa抗原を得た。ヒツジ赤血球上生理食
塩溶液で4回洗浄した後前述の奇弁らの文献「医学のあ
ゆみJ 78. 759.  l 971に記載の方法
に準じてクルタルアルデヒドで同定し、タンニン酸処理
全行い精製HBa抗原と反応せしめ、HBs抗原感作ヒ
ツジ赤血球を得た。
Example 1 Cloth HBa antigen was obtained from HBa anti-*+W plasma by a combination of ammonium sulfate fractionation, ion exchange chromatography, and ultracentrifugation. After washing 4 times with physiological saline solution on sheep red blood cells, it was identified with curtaraldehyde according to the method described in the above-mentioned paper by Chiben et al., ``The History of Medicine, J 78. HBs antigen-sensitized sheep red blood cells were obtained by reacting with the antigen.

生理食塩済液又は等張化リン酸緩衝液で洗浄し余分なH
Bs抗原を除去した後%5%11度の浮遊液とした。こ
の浮遊糸にそれぞれlチ(W/V) lllk度にyv
シン(コントロール)’k、1%(W /V)濃度にク
ルタチオン(コントロール)を又ハ、1〜8%(W/V
)m1度にウシアルブミン會添加し、ldずつ発注後凍
結乾燥を行った。
Wash with saline or isotonic phosphate buffer to remove excess H.
After removing the Bs antigen, it was made into a 5% suspension at 11°C. Each of these floating threads (W/V) llk to yv
Curtathione (control) at a concentration of 1% (W/V) and 1-8% (W/V)
) Bovine albumin was added to ml and freeze-dried after ordering ld.

凍結乾燥後、等張化リン酸緩衝液10d’i加え、再浮
遊液(0,5% (w/ v) 111度)とし検出感
度および陶性像の大きさ全観察した。
After freeze-drying, 10 d'i of isotonic phosphate buffer was added, and the suspension was resuspended (0.5% (w/v) at 111 degrees), and the detection sensitivity and size of the porcelain image were all observed.

凍結乾燥前の浮遊液も等張化リン酸緩衝液で0゜51 
(w/v)Ilfにi、1l11同時に試験した。
The suspension before freeze-drying is also adjusted to 0°51 with isotonic phosphate buffer.
(w/v) Ilf i, 1l11 were tested simultaneously.

また凍結乾燥品は4℃に保存し3チ月ごとに同様の試験
を行った。
The freeze-dried product was stored at 4°C and the same test was conducted every three months.

filに示す如くアルブミン無添加のもの及び1%(w
/v)以下のものでは凍結乾燥直後の検出JIJf#i
l/8〜l/16に低下するとともに隙性像も大きくな
り、凝集判定は国難となったoしかしアルブミン?l1
−2%(W/マ)以上加えたものは、いずれも凍結乾燥
直後の検出感度は変らず安定であった。
As shown in fil, those without albumin addition and 1% (w
/v) Detection immediately after freeze-drying for the following JIJf#i
As the temperature decreased from 1/8 to 1/16, the porosity image also increased, making the determination of agglutination a national problem.But albumin? l1
-2% (W/Ma) or more added was stable without any change in detection sensitivity immediately after freeze-drying.

凍結乾燥直後に検出感度が低下しなかったアルブミン2
56(W/マ)以上添加群につき4℃に保存し、更に長
期安定性試験を行り友。
Albumin 2 whose detection sensitivity did not decrease immediately after freeze-drying
The groups containing 56 (W/m) or more were stored at 4°C and further subjected to long-term stability tests.

アルブミン2s(W/V)添加では9チ月目で検出感度
がl/2に低下したが3%(w/マ)〜8% (W/V
)でUlBケ月後でも全く安定であった。このことから
アルブミンの添加量は、凍結乾燥時の長期安定化を図る
ためにId 2 To (w/v)以上、また凍結乾燥
直後および凍結乾燥後の長期安定化を図るためには3チ
(W/V)以上が好ましいことが判った。
When albumin was added at 2s (W/V), the detection sensitivity decreased to 1/2 at the 9th month;
) was completely stable even after several months of UlB. Therefore, the amount of albumin added should be Id 2 To (w/v) or more for long-term stability during freeze-drying, and 3 T (w/v) for long-term stability immediately after and after freeze-drying. W/V) or more was found to be preferable.

(以下余白) 実施例2 実施?!I 1と同様にして精1t!HBa抗原を、グ
ルタルアルデヒド処理およびタンニン酸処理したニワト
リ赤血球に感作した。
(Left below) Example 2 Implementation? ! Just like I 1, it's 1t! HBa antigen was sensitized to glutaraldehyde and tannic acid treated chicken red blood cells.

このHBa抗原感作ニワトリ赤血球の51 (W/v)
浮遊液にヒトアルブミンに5% (w/v) 濃fK加
え凍結乾燥した。
51 (W/v) of this HBa antigen-sensitized chicken red blood cell
5% (w/v) concentrated fK in human albumin was added to the suspension and freeze-dried.

凍結乾燥前後の検出感度および陰性像の大きさ等に差F
i認められなかった。
There is a difference in detection sensitivity and size of negative image before and after freeze-drying.
i was not recognized.

この凍結乾燥後の感作赤血球は4 ’Cで12ケ月間保
存した場合でも検出感度の低下は認められなかった。
Even when this freeze-dried sensitized red blood cell was stored at 4'C for 12 months, no decrease in detection sensitivity was observed.

実施例3 実施例1と同様にしてヒト0型赤血球を用いてHBa抗
原感作ヒ)O型赤血球浮遊液を得た〇このHBs抗原感
作ヒト0型赤血球の5 % (W/り浮遊液にウシアル
ブミンt496(w/v)濃度に加え凍結乾燥した。
Example 3 In the same manner as in Example 1, a suspension of type O red blood cells sensitized to HBa antigen using human type 0 red blood cells was obtained. Bovine albumin T496 (w/v) concentration was added to the sample and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった0 この凍結乾燥後の感作赤血球は4℃で12ケ月間保存し
た場合でも検出感度の低下は認められなかった。
No difference was observed in detection sensitivity and size of negative image before and after freeze-drying. Even when the freeze-dried sensitized red blood cells were stored at 4°C for 12 months, no decrease in detection sensitivity was observed.

実施例4 HBe抗原t−HBe抗体結合セファロースで梢製し、
以下実施例1と同様にしてHBt4涼感作ヒツジ赤血球
浮遊液會得た。
Example 4 HBe antigen t-HBe antibody conjugated with Sepharose,
Thereafter, an HBt4 cool sensitized sheep red blood cell suspension was obtained in the same manner as in Example 1.

このHBe抗原感作ヒツジ赤血球の5%(W/v)浮遊
液にウシアルブミンに59b (w/v)mWに加え凍
結乾燥した。
59b (w/v) mW of bovine albumin was added to a 5% (w/v) suspension of the HBe antigen-sensitized sheep red blood cells and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。またこの凍結乾燥後の感作赤血球は
4℃で15ケ月間保存した場合でも検出感度の低下は認
められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying. Furthermore, no decrease in detection sensitivity was observed even when the sensitized red blood cells after freeze-drying were stored at 4° C. for 15 months.

実施例5 抗HBsモルモット血清より硫安分画法およびDEAE
−セルロースイオン交換吸着法により精製HBa抗体會
得た。
Example 5 Ammonium sulfate fractionation and DEAE from anti-HBs guinea pig serum
- Purified HBa antibody was obtained by cellulose ion exchange adsorption method.

この抗体を用い実施?!I lと同様にして抗HBs抗
体感作ヒツジ赤血球浮遊at−得た。
Is this carried out using this antibody? ! An anti-HBs antibody-sensitized sheep red blood cell suspension was obtained in the same manner as in Il.

この抗HBa感作ヒツジ赤血球の5%(W/V)浮遊液
にウシアルブミンを3%(W/V)allfK加え凍結
乾燥した。
Bovine albumin was added to 3% (w/v) allfK to this 5% (w/v) suspension of anti-HBa sensitized sheep red blood cells and freeze-dried.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。またこの凍結乾燥後の感作赤血球F
i4℃で18ケ月間保存した場合でも検出感度の低下は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying. In addition, this sensitized red blood cell F after freeze-drying
No decrease in detection sensitivity was observed even when stored at 4°C for 18 months.

実施例6 抗ヒトインターフェロン(ロ)ウマ血清より、DEAE
−セファデックスおよびヒFインターフエpン結合セフ
ァロース4Bt−用いて抗ヒトインターフェロンウマ抗
体を精製した。
Example 6 Anti-human interferon (RO) DEAE from horse serum
Anti-human interferon horse antibodies were purified using Sephadex and HiF interferon-conjugated Sepharose 4Bt.

この精製抗体を用い実施例1と同様にして抗ヒトインタ
ーフェロン感作ヒツジ赤血球1得た。
Using this purified antibody, anti-human interferon sensitized sheep red blood cells 1 were obtained in the same manner as in Example 1.

この抗ヒトインターフェロン感作ヒツジ赤血球の5%(
w/v)浮遊液にヒトアルブミンt−5%(v/V)1
11度に加え凍結乾燥した。
5% of this anti-human interferon sensitized sheep red blood cells (
w/v) human albumin t-5% (v/v) 1 in suspension
11 degrees and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying.

実施例7 抗ヒトウロキナーゼウサギ血清より、硫安分画、ポリエ
チレングリコール分画およびDEAE−セルロースクロ
マトグラフィー法ケ用いて抗ヒトウロキナーゼ抗体を精
製した。この精製抗体を用い実施例1と同様にして、抗
ヒトウロキナーゼ感作ヒツジ赤血球浮遊液を得た。
Example 7 Anti-human urokinase antibody was purified from anti-human urokinase rabbit serum using ammonium sulfate fractionation, polyethylene glycol fractionation, and DEAE-cellulose chromatography. Using this purified antibody, an anti-human urokinase-sensitized sheep red blood cell suspension was obtained in the same manner as in Example 1.

この抗ヒトウロキナーゼ感作ヒツジ赤血球の5%(w/
v)浮遊液にウシアルブミンを2チ(W/V)濃度に加
え凍結乾燥した。
5% (w/
v) Bovine albumin was added to the suspension at a concentration of 2% (W/V) and freeze-dried.

凍結乾燥前後の検出If&度および陰性欅の大きさ等に
差は認められなかった。
No difference was observed in the detection If&degree and the size of negative Keyaki before and after freeze-drying.

実施例8 アルファフェトプロチン陽性ヒト腹水よりイオン交換吸
着法、ゲルろ過性および抗アルファ7エトプロテン抗体
結合セファロース吸着法ケ用いてMli!フル7ア7エ
トプロテンを得た。
Example 8 Alpha-fetoprotin-positive human ascites was purified using ion-exchange adsorption, gel filtration, and anti-alpha-7 ethoprotene antibody-conjugated Sepharose adsorption to obtain Mli! Full 7a7 ethoprotene was obtained.

このアルファフェトプロチンを用い実施tHJ lと同
様にしてアルファフエトグロテy感作ヒツジ赤血球浮遊
液を得た。
Using this alpha-fetoprotin, a suspension of alpha-fetoglot-sensitized sheep red blood cells was obtained in the same manner as in the tHJ1 experiment.

このアルファフェトプロチン感作ヒツジ亦血球の5%(
W/v)浮遊液にウシまたはヒトアルブミンを51(w
/v)濃度に加え凍結乾燥した。
This alpha-fetoprotin sensitized sheep has 5% of blood cells (
51 (w/v) bovine or human albumin was added to the suspension.
/v) concentration and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying.

この凍結乾燥後の感作赤血球は4℃で12ケ月間保存し
fc、場合でも検出感度の低下Fi認められなかった。
The sensitized red blood cells after freeze-drying were stored at 4° C. for 12 months, and no decrease in detection sensitivity was observed even in the case of fc.

サイログロブリンVS製した0この*裂抗原金用い実施
例1と同様にしてサイログロブリン感作ヒツジ赤血球浮
遊液會得た。
A thyroglobulin-sensitized sheep red blood cell suspension was obtained in the same manner as in Example 1 using the *0 cleft antigen gold produced by thyroglobulin VS.

この5%(w/v)浮遊液にヒトアルブミンを5% (
W/V)濃度に加え凍結乾燥した。
To this 5% (w/v) suspension, add 5% human albumin (
W/V) concentration and lyophilized.

凍結乾燥前後の検出IIA度および陰性像の大きさ等に
差は認められなかった。
No difference was observed in the detection degree of IIA and the size of negative images before and after freeze-drying.

実施例IO 抗ヒト胎盤性ゴナドトロピンヒツジ血清より硫安分画、
DEAE−セルロースクロマトグラフィー法ケ用いて抗
ヒト胎盤性ゴナドトロピン抗体を精製した。この精製抗
体を用い実施例1と同様にして抗ヒト胎盤性ゴナドトロ
ピン抗体感作赤血球浮遊液を得た。
Example IO Anti-human placental gonadotropin ammonium sulfate fraction from sheep serum,
Anti-human placental gonadotropin antibodies were purified using DEAE-cellulose chromatography method. Using this purified antibody, an anti-human placental gonadotropin antibody-sensitized red blood cell suspension was obtained in the same manner as in Example 1.

この5%(w/v)浮遊液にウシアルブミン全5饅(w
/v)1度に加え凍結乾燥した。
To this 5% (w/v) suspension, all 5 pieces of bovine albumin (w) were added.
/v) once and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying.

実施例11 抗ヒツジ赤血球ウサギ血清より硫安分画、DEAE−セ
ルロースクロマトグラフィー法を用いて抗ヒツジ赤血球
ウサギ抗体t−haした。この精製抗体を用い実施例1
と同様にして抗ヒツジ赤血球つサギ抗体ヒ)O型赤血球
浮遊液會得た。
Example 11 An anti-sheep red blood cell rabbit antibody t-ha was produced using ammonium sulfate fractionation from anti-sheep red blood cell rabbit serum and DEAE-cellulose chromatography. Example 1 using this purified antibody
In the same manner as above, an anti-sheep red blood cell suspension (human type O red blood cell suspension) was obtained.

この5%(w/v)浮遊液にヒトアルブミン會5チ(w
/v)(11度に加え凍結乾燥し友。
To this 5% (w/v) suspension, 5 h (w) of human albumin was added.
/v) (11 degrees plus freeze-dried.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying.

実施例12 ヒトバセドウ病患者の甲状腺組賊よシ超高速遠心分画法
によシミクロシーム會分離した。このξクロシームを実
施例1と同様にしてバセドウ病のミクロゾーム感作ヒツ
ジ赤血球浮遊液會得た。
Example 12 Thyroid tissue from a human Graves' disease patient was isolated by ultrahigh-speed centrifugal fractionation. This ξcroseam was used in the same manner as in Example 1 to obtain a suspension of microsomal sensitized sheep red blood cells with Graves' disease.

この5%(W/V)浮遊液にウシアルブミンts% (
w/v)濃度に加え凍結乾燥した。
Bovine albumin ts% (
w/v) concentration and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差F
i認められなかった。
There is a difference in detection sensitivity and size of negative image before and after freeze-drying.
i was not recognized.

実施例13 溶血性連鎖球菌の培養ろ液より硫安分画法を用いストレ
プトリジン0、ストレプトキナーゼを精製した。これら
の精製抗原上用い実施例1と同様にしてストレプトリジ
ン0感作ヒツジ赤血球浮遊液およびストレプトキナーゼ
感作ヒツジ赤血球浮遊液を得た。
Example 13 Streptolysin 0 and streptokinase were purified from a culture filtrate of hemolytic streptococci using an ammonium sulfate fractionation method. Using these purified antigens, a streptolysin 0-sensitized sheep red blood cell suspension and a streptokinase-sensitized sheep red blood cell suspension were obtained in the same manner as in Example 1.

この5%(W/V)浮遊液にヒトアルブミンを5チ(w
/v)m1度に加え凍結乾燥した。
Five grams of human albumin (w/w) was added to this 5% (w/v) suspension.
/v)ml and freeze-dried.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
紹められなかった。
No differences were observed in detection sensitivity or size of negative images before and after freeze-drying.

実施例14 ブドウ球菌、緑膿菌、肺炎双球菌、肺炎桿菌、大腸菌、
インフルエンザ劇、ルイコプラズマ、トキソプラズマな
どの菌体膜成分を破音波破壊法、フェノール水加温法な
どで抽出し、また破傷風−、ガスー威菌の菌体外毒素全
硫安分画法でN製した。これら會実施例1と同様にして
菌体膜あるいは菌体外毒素感作ヒツジ赤血球浮遊液會得
た。
Example 14 Staphylococcus, Pseudomonas aeruginosa, Diptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli,
Bacterial membrane components of influenza, Leucoplasma, Toxoplasma, etc. were extracted by sonic destruction method, phenol water heating method, etc., and extracellular toxins of Tetanus and G. . A bacterial membrane or an exotoxin-sensitized sheep red blood cell suspension was obtained in the same manner as in Example 1.

この5%(w/v)浮遊液にウシアルブミンを5% (
W/v)濃度に加え凍結乾燥した。
Bovine albumin was added to this 5% (w/v) suspension at 5% (
w/v) concentration and lyophilized.

凍結乾燥前後の検出感度および陰性像の大きさ等に差は
認められなかった。
No difference was observed in detection sensitivity or size of negative image before and after freeze-drying.

実施例15 ヒツジ赤血球、ニワトリ赤血球、ヒト0型赤血球、ガチ
ョウ赤血球、ウシ赤血球およびウサギ赤血球全生理食塩
溶液で4回洗浄後、フォルムアルデヒド又はグルタルア
ルデヒドで処理し残余のフォルムアルデヒド又はグルタ
ルアルデヒド會遠心分離法で除去した。これら固定赤血
球の1部tタンニン酸処理し、残余のタンニン酸を遠心
分離法で除去し友。これら固定赤血球およびタンニン酸
処理赤血球の4−浮遊液に、ヒトアルブミン、ウシアル
ブミン又はウマアルブミンを終111mが2s(W/マ
)および5%(W/V)になるように添加し凍結乾燥し
fC,)凍結乾燥後、等銀化リン酸緩飯液會加えて再浮
遊せしめ、同じ等銀化リン酸緩衝液に対する反応を赤血
球沈降像の直径全測定することによ)比較した02〜5
%(w/v)のフルブミン添加凍結乾燥後のそれぞれの
赤血球はいずれも凍結乾燥前のそれと比べ変化は認めら
れなかったが、アルブミン無添加の状態で凍結乾燥した
ものはいずれも赤血球沈降像の直径が大きくな択凍結乾
燥により性状が変化していることが推測された〇
Example 15 Sheep erythrocytes, chicken erythrocytes, human type 0 erythrocytes, goose erythrocytes, bovine erythrocytes, and rabbit erythrocytes were washed four times with whole physiological saline solution, treated with formaldehyde or glutaraldehyde, and the remaining formaldehyde or glutaraldehyde centrifugation. removed by law. A portion of these fixed red blood cells was treated with tannic acid, and the remaining tannic acid was removed by centrifugation. Human albumin, bovine albumin, or horse albumin was added to a suspension of these fixed red blood cells and tannic acid-treated red blood cells at a final concentration of 2 s (W/ma) and 5% (W/V) and freeze-dried. fC,) After lyophilization, the samples were resuspended in an equal silver phosphate buffer solution, and the reaction to the same silver phosphate buffer was compared by measuring the total diameter of the erythrocyte sedimentation image.02-5
% (w/v) of each erythrocyte after lyophilization with the addition of fulbumin, no change was observed compared to that before lyophilization, but the erythrocyte sedimentation image of each erythrocyte lyophilized without albumin was It was inferred that the properties changed due to selective freeze-drying with a larger diameter.〇

Claims (3)

【特許請求の範囲】[Claims] (1)  赤血球の水浮遊液にアルブミン? 2 % 
(v/マ)濃度以上となるように添加して凍結乾燥する
ことt−特徴とする赤血球凍結乾燥物の製造方法0
(1) Is there albumin in the water suspension of red blood cells? 2%
(v/ma) Addition to a concentration higher than that and lyophilization t-Method for producing lyophilized red blood cells characterized by 0
(2)赤血球が固定赤血球である特許請求の範囲第(1
)項記載の赤血球凍結乾燥物の製造方法。
(2) Claim No. 1 in which the red blood cells are fixed red blood cells
) The method for producing a lyophilized red blood cell as described in section 2.
(3)赤血球が任意の抗原又は抗体ケ感作せしめた感作
赤血球である特許請求の範囲第(1)項記載の赤血球凍
結乾燥物の製造方法。
(3) The method for producing lyophilized red blood cells according to claim (1), wherein the red blood cells are sensitized red blood cells sensitized with any antigen or antibody.
JP57013862A 1982-01-29 1982-01-29 Preparation of lyophilized erythrocyte Granted JPS58131913A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57013862A JPS58131913A (en) 1982-01-29 1982-01-29 Preparation of lyophilized erythrocyte

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57013862A JPS58131913A (en) 1982-01-29 1982-01-29 Preparation of lyophilized erythrocyte

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP57072253A Division JPS58131566A (en) 1982-04-28 1982-04-28 Lyophilized matter of red blood cell

Publications (2)

Publication Number Publication Date
JPS58131913A true JPS58131913A (en) 1983-08-06
JPH0459299B2 JPH0459299B2 (en) 1992-09-21

Family

ID=11845063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57013862A Granted JPS58131913A (en) 1982-01-29 1982-01-29 Preparation of lyophilized erythrocyte

Country Status (1)

Country Link
JP (1) JPS58131913A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004329A1 (en) * 1988-10-20 1990-05-03 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CN102327289A (en) * 2011-10-17 2012-01-25 济南环肽医药科技有限公司 Erythrocyte freeze-dried powder preparation for injection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4921052A (en) * 1972-06-16 1974-02-25
JPS5228485A (en) * 1975-07-18 1977-03-03 Behringwerke Ag Polyionic isotonic salt solution
JPS5423119A (en) * 1977-07-25 1979-02-21 Takeda Chem Ind Ltd Erythrocyte for haemagglutination test
JPS577419A (en) * 1980-06-17 1982-01-14 Toshiba Kagaku Kogyo Kk Erythrocyte storing solution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4921052A (en) * 1972-06-16 1974-02-25
JPS5228485A (en) * 1975-07-18 1977-03-03 Behringwerke Ag Polyionic isotonic salt solution
JPS5423119A (en) * 1977-07-25 1979-02-21 Takeda Chem Ind Ltd Erythrocyte for haemagglutination test
JPS577419A (en) * 1980-06-17 1982-01-14 Toshiba Kagaku Kogyo Kk Erythrocyte storing solution

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004329A1 (en) * 1988-10-20 1990-05-03 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
JPH04501112A (en) * 1988-10-20 1992-02-27 クールター コーポレーション Method for producing stabilized and freeze-dried mammalian cells
CN102327289A (en) * 2011-10-17 2012-01-25 济南环肽医药科技有限公司 Erythrocyte freeze-dried powder preparation for injection and preparation method thereof

Also Published As

Publication number Publication date
JPH0459299B2 (en) 1992-09-21

Similar Documents

Publication Publication Date Title
US4757024A (en) Immune complex detection method and article using immunologically non-specific immunoglobulins
US3553310A (en) Immunologically reactive particles
US3714345A (en) Stabilized erythrocyees and methods therefore
US4332783A (en) Process for immunologic determination tests
Stavitsky et al. Studies of Proteins and Antibodies by Specific Hemagglutination and Hemolysis of Protein-Conjugated Erythrocytes (Part 2 of 2)
CA1195925A (en) Method for assaying antigen-antibody reactions and reagent therefor
Porter Porcine colostral IgA and IgM antibodies to Escherichia coli and their intestinal absorption by the neonatal piglet
US4118349A (en) Process for the manufacture of polystyrene latex compounds
CA1168580A (en) Immunological reagent for the detection of tubes of the rheumatoid factor in a biological specimen and process for preparing this novel reagent
US3639559A (en) Method of isolating antigens and/or antibodies from protein mixtur
US5318913A (en) Reagent for the determination by hemagglutination of antibodies to bacterial toxins, method of preparation and application thereof
US4096138A (en) Immunological test procedure
US5302512A (en) Agglutinant complex as blood typing reagent
US4218335A (en) Stabilizer for an immunochemical measuring reagent
US5660978A (en) Stabilization of analytes
Deutsch et al. Immunochemical properties of heated ovomucoid
JPS58131913A (en) Preparation of lyophilized erythrocyte
JPS62209362A (en) Composition for immune agglutination
Lauf et al. Solubilization and structural integrity of the human red cell membrane
US4460694A (en) Bovine glycoproteins and use in diagnosing infectious mononucleosis
Lee et al. Sheep erythrocyte agglutinins and beef erythrocyte hemolysins in infectious mononucleosis serum
JPS58131566A (en) Lyophilized matter of red blood cell
US3925541A (en) Method of coating stabilized erythrocytes
Goodger et al. Babesia bovis (argentina): studies on the composition and location of antigen associated with infected erythrocytes
JPS6215464A (en) Non-specific reaction absorbent for reverse passive agglutination reaction